As the geriatric population is growing, it is increasingly important to be familiar with chemotherapy for the elderly. Age-related changes in pharmacokinetics are documented for doxorubicin, etoposide, ifosfamide, daunorubicin, mitomycin, cisplatin and methotrexate. The hematological toxicity of most standard-dose chemotherapy is not affected by age in patients with normal organic functions and good performance status, although increased toxicity with aging is suggested in the use of actinomycin-D, etoposide, vinblastin, methotrexate, methyl-CCNU, doxorubicin and mitomycin, and in dose-intensive chemotherapy. Among non-hematological toxicities, only doxorubicin-induced cardiomyopathy and bleomycin-induced pulmonary toxicity are demonstrated to be accelerated in the elderly. There is no evidence that advanced age decreases the efficacy of chemotherapy for tumors, except for Hodgkin's disease and acute leukemia. These results suggest that advanced chronological age alone is not always associated with severe toxicity and poor prognosis, and that many elderly patients with cancer will benefit from chemotherapy. To answer questions regarding the optimal chemotherapy regimen, dose and intensity in this population, the influence of age should be analyzed in a multivariate approach in future studies.
INTRODUCTION
Since the incidence of cancer increases with age, cancer therapy for the elderly is one of the major issues in medical oncology as the geriatric population is growing. There has been a general tendency among physicians to consider that aged people always have poor tolerance to chemotherapy and, in consequence, many elderly patients with cancer have been undertreated for fear of excessive toxicity (1) (2) (3) (4) . However, there is little evidence from clinical studies that they should be treated with lower dosages of antineoplastic agents than younger patients. This review deals with a large variety of conflicting opinions concerning the benefit and toxicity of cytotoxic drugs in the elderly, based on associations between age and both pharmacokinetics (PK) and pharmacodynamics (PD), as well as normal changes in aging organs that are targets of antineoplastic agents.
AGE AND PHARMACOKINETICS OF ANTINEOPLASTIC AGENTS
Pharmacologic effects, both therapeutic and toxic, are functions of the intensity and duration of exposure to a drug (5) . Drug exposure is affected by the processes of drug absorption, distribution, metabolism and excretion. It is well known that these processes are influenced by physiological changes of organs with aging (Table 1) (6,7), but there are only a limited number of human studies on PK of antineoplastic agents in the elderly (Table 2) . ABSORPTION Changes in the function of the gastrointestinal tract in old age include impaired acid secretion, and decreased absorptive surface, splanchnic blood flow and gastrointestinal motility (7, (20) (21) (22) . However, absorption of most antineoplastic agents administered orally does not seem to change with age (23, 24) . Possible exceptions are procarbazine, methotrexate and leucovorin, but no PK data on these drugs are available (23, 24) . 
Excretion
Adapted from Montamat et al. (6) .
Increased gastric pH, decreased absorptive surface, decreased splanchnic blood flow, decreased gastrointestinal motility Decreased cardiac output, decreased total body water, decreased lean body mass, increased body fat, decreased serum albumin, increased alpha-acid glycoprotein Decreased hepatic mass, decreased hepatic blood flow, decreased activity of metabolic enzyme Decreased renal blood flow, decreased glomerular filtration rate, decreased tubular secretion 
DISTRIBUTION
The distribution of a drug depends largely on its relative aqueous and lipid solubility, the degree of its binding to plasma proteins and specific tissues, and the total blood flow (25) . A decrease in lean body mass and total body water, and an increase in body fat, which are well-documented body compositional alterations in the elderly (26) (27) (28) , affect the volume of distribution and the elimination half-life of a drug (7, 23) . The early clearance of doxorubicin declines significantly with age (8) . Since early-phase PK of this drug is associated with its tissue binding, this decline can be due to decreased lean body mass in the elderly (29) . The volume of distribution and the half-life of ifosfamide (9) and etoposide (10) are increased in elderly patients, probably because these drugs are lipophilic and readily accumulate in lipid-rich tissues. For antineoplastic agents that are highly bound to plasma proteins, such as etoposide, doxorubicin, methotrexate, platinum and taxanes, a decrease in the plasma albumin level would increase the concentration of the unbound fraction of total drug in the plasma, and result in a large volume of distribution because more drug would be free to be distributed to peripheral tissue (23, 30) . However, the albumin value in the elderly varies, with reports from a 20% decrease (31, 32) to almost normal values (33, 34) . These conflicting results may be attributable to a lack of longitudinal studies and difficulty in excluding subjects with underlying chronic diseases (35) .
METABOLISM
Liver size decreases by 18-44% between the ages of 20 and 80 years, and hepatic blood flow declines at a rate of 0.3-1.5% per year after the age of 25 (36) . In consequence, first-pass metabolism of flow-dependent drugs would be reduced, leading to higher plasma concentrations and reduced systemic clearance of the drugs. The process of hepatic metabolism involves two types of reactions: phase I, consisting of oxidation, reduction and hydrolysis which primarily occur via the cytochrome p450 microsomal system; and phase II, consisting of conjugation reactions. Phase II reactions appear to be unaffected by age, whereas association between age and enzyme activity involving phase I reactions is controversial (37, 38) . Although studies on cytochrome P450 in human liver biopsy specimens show no significant association between monooxygenase activity and age of patients (39, 40) , the liver clearance of many non-cytotoxic drugs such as antipyrine is reduced in the elderly (7, 41, 42) . Daunorubicin and its active metabolite daunorubicinol are eliminated mainly from the liver (29). Egorin et al. (11) showed that the area under the curve of time versus plasma concentration (AVC) of daunorubicin did not change with age, but that of daunorubicinol increased by 2-4 times in patients aged~60 years compared to younger patients. However, others reported that plasma clearance of neither compound was affected by age (12) . The AVC of mitomycin is also increased with age, probably due to altered hepatic metabolism of the drug (13).
EXCRETION
Both renal structure and function deteriorate with aging (43, 44) . Renal weight, renal blood flow, the number of functioning glomeruli and the glomerular filtration rate decline in a linear fashion after the age of 30 years (43, 44) , and therefore the clearance of drugs which are eliminated mainly from this organ is reduced. The AVC of cisplatin, measured for both ultrafilterable platinum and total plasma platinum, is significantly increased with age (14) . The overall elimination half-life of methotrexate is inversely related to creatinine clearance and is prolonged in the elderly (15) . The clearance of fluorouracil, busulfan, piroxantron, paclitaxel and topotecan seems unaffected by age (17) (18) (19) .
PHARMACODYNAMICS AND AGING
Pharmacodynamics describe the relationship between exposure of cells to antineoplastic drugs and their pharmacological effects. In a clinical setting, these effects are manifested as toxicity and tumor response. Elderly patients often have concomitant diseases and/or organ dysfunction. Co-morbidity may influence the severity of chemotherapy-related toxicity, and indication for chemotherapy would be restricted by decreased functional capacity of the organ. In elderly cancer patients without complications, however, there is no agreement as to whether or not age is associated with an increase in various toxicities (24) . Their frequency, nature and severity vary with the drug, dose and administration schedule.
MYELOTOXICITY
Physiologicalhematopoieticcapacity is affected by aging. The bone marrow with hematopoietic function decreases in volume with age and is confmed mainly within the spine, pelvis and sternum in the elderly (45) . The cellularity in the iliac bone decreases with age, from >80% at under age 10 years to <30% at over age 70 years, as estimated from studies using magnetic resonance imaging (MRI) and histological sections (45) (46) (47) . The number of hematopoietic progenitor cells per unit volume of bone marrow does not change with age in humans, except for a slight decrease in the erythroid system (48) (49) (50) , but the number of these cells circulating in the peripheral blood is reduced in the elderly (51, 52) . Serum levels of hematopoietic growth factors are well maintained in the elderly (53, 54) , but responses of hematopoietic cells to these factors vary with the report (50) (51) (52) (55) (56) (57) . Changes in the marrow microenvironment may also be associated with hematopoietic function of old people (58, 59) . These results indicate that marrow hematopoietic cells generally continue to function well in the elderly, but that the reserve capacity is reduced because of a decrease in the absolute amount of hematopoietic marrow.
The toxicity of single-agent chemotherapy has been evaluated in phase I and phase II clinical trials of investigational anticancer drugs (Table 3) . There is no difference in the incidence of grade 3-4 hematological toxicity between old and younger patients, or in the actual delivered dose and the number of treatment courses, dose reduction, treatment interruption and days of delay (60) (61) (62) (63) Hematological toxicity in the elderly who receive combination chemotherapy seems to depend on the drug contained in the regimen and the intensity of the treatment. Using a regression model, Begg et al. (64) calculated the odds ratio (OR) of each cytotoxic drug for grade 3-4 hematological toxicity in elderly patients who were treated with combination chemotherapy. This study combined the results of 95 Eastern Cooperative Oncology Group (ECOG) clinical trials between 1971 and 1984, involving 290 treatment arms and 16580 patients comprising 8787 patients aged <60 years, 5584 aged 60-69 years and 2209 aged~70 years. They concluded that the incidence of toxicity was not affected by age for most of the agents, but that the following six drugs were significantly associated with a higher risk of severe hematological toxicity for patients at the age of~70 years: actinomycin-D, OR =4.2; etoposide, OR =2.6; vinblastin, OR = 2.5; methotrexate, OR = 2.2; methyl-CCNU, OR = 1.5; doxorubicin, OR = 1.4.
However, this study included both previously treated and untreated patients, and did not evaluate interaction between drugs or dose-response effects. Clinical trials comparing toxicity between elderly and younger patients with various malignant diseases are summarized in Tables 4 and 5 . In general, the degree of hematological toxicity of combination chemotherapy for solid tumors seems not to differ between elderly and younger patients, but is more severe in patients over 70 years old receiving mitomycin-containing chemotherapy (69) . For hematological malignancies, most chemotherapy regimens are more toxic for patients of advanced age. The CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone) for non-Hodgkin's lymphoma, however, is well tolerated regardless of age (74) . These results indicate that (i) the hematological toxicity of most standard-dose chemotherapy is not affected by age; (ii) the following drugs seem to be associated with more severe hematological toxicity in the elderly: actinomycin-D,etoposide, vinblastin, methotrexate, methyl-CCNU, doxorubicin and mitomycin; (iii) intensive chemotherapy is more likely to be highlytoxic in the elderly, especially in those with hematological malignancies.
INFECTIONS
Elderly patients can be predisposed to infection during chemotherapy because of impaired immune function as well as neutropenia (77, 78) . The marked feature of immunosenescence is a decline in T-cell-mediated immunity, which is primarily attributable to completion of thymic involution by the age of 50 years (79, 80) . Intrathymic T-cell selection and maturation are impossible, and therefore the supply of new naive T cells from the thymus to the periphery is diminished in the elderly. In consequence, the number of naive T cells decreases, but that of memory T cells increases with aging because antigen-driven conversion of naive to memory cells still continues throughout life (79, 81, 82) . The responsiveness of T cells to antigens and mitogens seems to decline in the elderly, which is explained at least in part by increased rigidity of the plasma membrane, decreased surface expression of co-stimulatory molecules, and altered signal transduction pathways of T cells in the elderly (79, 81, 83) . Production of interleukin (IL)-2 (84,85) and expression ofIL-2 receptors (85,86) in T cells decrease with age, leading to impaired clonal expansion of these cells (81) . Age-associated alterations are also noted in the production of other cytokines, such as IL-4, IL-6, IL-10, interferon-gamma, tumor necrosis factor-alpha and transforming growth factor-beta (79, 81) . Impaired humoral immunity in the elderly is mainly caused by dysfunction of T cells that regulate B-cell activation and differentiation (79, 81, 83) . Production and affinity maturation of antibody in response to antigen decline in the elderly (83, 87, 88) . Changes in function of antigen-presenting cells such as macrophages and dendric cells are controversial (89) (90) (91) .
In spite of age-related dysfunction in the immune system described above, there is little evidence that the incidence of infection during chemotherapy increases with age. Dixon et al. (92) showed that pneumonia occurred in 10% of patients aged <60 years, but in 47% of patients aged 260 years, who received combination chemotherapy for small cell lung cancer, although the incidence of prolonged neutropenia did not differ between the two age groups. Febrile episodes are also more common in elderly patients with this disease (67, 68) . A higher incidence of severe infection and death as a result of sepsis was observed in elderly patients during treatment of leukemia (93, 94) . In other malignancies, however, no difference is noted in the occurrence of infection between elderly and younger patients (65, 72, 73, 95) . Abbreviations: A, ara-C; Az, 5-azacytidine; B, carmustine (BCND); Ble, bleomycin; C, cyclophosphamide; Cc, lomustine (CCNU); CR, complete response rate; D, daunorubicin; Dex, dexamethasone; E, etoposide; H, adriamycin; m, m-AMSA; M, mechlorethamine; mel, nelphalan; MST, median survival time; 0, vincristine; P, prednisone; Pr, procarbazine; T, 6TG; V, vinblastine; WBC, white blood cell. *Percentage of toxic death. tBoth complete and partial responses are included.
CARDIOTOXICITY
The heart changes with age in both structure and function (96) (97) (98) (99) . Moderate left ventricular hypertrophy, increased circumference of the aortic and pulmonary valves, fibrotic thickness and calcification of the valves, and tortuous and focally calcified coronary arteries are found in the aging heart. Loss of myocytes and an increase in matrix connective tissue are observed in the aged myocardium, and these changes are more pronounced in the male heart than in the female heart. There are also atrophy and loss of specialized conduction tissue in the atria and ventricles. Cardiac functions at rest do not change with aging, but chronotropic response to beta-sympathetic stimulation and maximum work capacity of the heart decline significantly in the elderly (96, 100) . Abnormal findings in electrocardiography (ECG) are observed in 57% of the elderly aged :2:65 years, and 80% of the abnormality is associated with dysfunction of the conduction system (101) . By 24 h ambulatory ECG, paroxysmal atrial tachycardia and ventricular tachycardia were detected in 13 and 4%, respectively, of98 healthy people aged :2:60 years (102).
In a large population-based study, the incidence of ventricular tachycardia was found to have increased significantly with age, although serious arrhythmias were uncommon (103) . Exerciseinduced non-sustained ventricular tachycardia was observed in 0.15% of healthy volunteers aged <65 years and 3.75% of those aged :2:65 years (104). Thus, arrhythmias are common in the elderly even if they complain of no symptoms. Cardiotoxicity is a major limiting factor in the use of anthracyclines, including doxorubicin and daunorubicin. Doxorubicin-induced cardiotoxicity can be classified into three categories: acute toxicity consisting of supraventricular or ventricular tachycardias, subacute consisting of toxic myocarditis or pericarditis, and chronic consisting of cumulative dilated cardiomyopathy (105) . Age, as well as total dose of drug administered, the schedule of administration, pre-existing cardiac disease, and radiotherapy to the mediastinum, are the established risk factors for doxorubicin-induced dilated cardiomyopathy (105-111). Bristow et al. (108) recommended that the total dose of doxorubicin should be limited within 300 mg/rn? for patients :2:70 years of age. Cardiotoxicity of daunorubicin is equivalent to that of doxorubicin, but few reports are focused on damage to the heart by the drug in the elderly (105, 112) . For other cytotoxic agents, there is no proven correlation between age and the degree of cardiotoxicity (95, 105, 106) .
PULMONARY TOXICITY
It is well established that lung function declines in the elderly (113) . The vital capacity and forced expiratory volume in the first second decrease, and the residual volume increases with age as a result of the diminished elastic force of the lung. The increased closing volume in the elderly promotes collapse of small conducting airways, non-uniformity of alveolar ventilation and air trapping. Diffusion capacity also decreases with age, and this is associated with uneven distribution of the inspired gas and blood flow within the lung, decreased gas-exchange surface, and resistance to transfer of gas molecules from gas phase to the hemoglobin molecule. In contrast to physiological changes, morphology in the aging lung is not conclusive because it is often difficult to distinguish changes in the lung with age from those due to smoking and other environmental exposures (114) . The number of alveoli per unit lung volume decreases and the amount of emphysema increases with age even in non-smokers. Alterations in the amount and nature of elastic and collagen tissues vary with reports, but most of them show no or only subtle changes. These physiological and anatomical changes with age probably compromise the ability to clear pathogens arriving in the lung through the airways, but their effects on the responses of the lung to agents arriving in the lung through the blood stream are unknown.
The incidence of pulmonary toxicity due to antineoplastic agents is variable, partly because of the different diagnostic criteria employed and difficulty in excluding other causes such as infection (115) .
Among many anticancer drugs causing pulmonary toxicity, only bleomycin is shown to be associated with increased toxicity in the elderly (115) (116) (117) (118) . Bleomycin directly injures the pulmonary capillary endothelium and type I pneumocytes, leading to diffuse alveolar damage and interstitial fibrosis (115) . Pulmonary toxicity of the drug is manifested by cough, dyspnea and bilateral pulmonary infiltrates on chest X-ray films, with an incidence of -3% of patients receiving a total dose of <450 units of bleomycin (115, 116) . Established risk factors for the toxicity are age >70 years, cumulative dose >450 units, thoracic radiotherapy and a high inspired concentration of oxygen. Bleomycin pulmonary toxicity occurs in 10--50% of patients with one or more of these factors (115) (116) (117) (118) . Interstitial pneumonitis accompanying bone marrow transplantation is the other example of chemotherapyrelated pulmonary toxicity increasing with age (115, 119) .
NEUROTOXICITY
Apart from loss of neurons and degenerative changes such as accumulation of lipofuscin, altered structure and function of the central nervous system in the elderly are not clearly understood (120, 121) . On MRI scanning of the brain, a diffuse periventricular white matter change is frequently detected in the elderly. This is usually reported as secondary to microvascular leukoencephalopathy, but evidence of an actual pathological correlation is scant (122) . The influence of aging on cerebral blood flow is inconsistent among reports, but most show a decline in this parameter with age (122) (123) (124) (125) . This age-related decrease in blood flow of the brain is enhanced by cerebral arterial sclerosis even in the absence of any ischemic symptoms (124, 126) . In contrast, metabolism of the brain is well maintained throughout life (122) . The function of the blood-brain barrier seems to be affected by age, and therefore the brain's susceptibility to drugs may be increased (127) (128) (129) .
Basic alterations in aged peripheral nerves, axonal degeneration, secondary demyelination, and subsequent loss of myelinated fibers, are more prominent in thick nerve bundles and their distal part (121) . The conduction velocity of peripheral nerves decreases with age (130) . With these changes, elderly patients are considered to be at higher risk of peripheral neuropathy.
A common manifestation of central neurotoxicity is white matter changes (131, 132) . Following high-dose cytarabine therapy, encephalopathy, cerebellar dysfunction and peripheral neuropathy have been observed. Gottlieb et al. (133) claimed that this neurotoxicity is age related, but another study found no association between the neurotoxicity and patient age after adjustments for renal insufficiency (134) . Hearing loss associated with cisplatin administration may be affected by age (135) . In the treatment of Hodgkin's disease, increased neurotoxicity with age was noted, which is attributable to vincristine (70) . However, no difference in neurotoxicity was observed between young and old patients with non-Hodgkin lymphoma who were treated with the CHOP regimen (72) , and those with lung cancer who received combination chemotherapy containing vinca alkaloids and cisplatin (68, 69) . An analysis of patients who received chemotherapy for colorectal cancer, sarcoma, and head and neck cancer also disclosed no difference in neurotoxicity (95) .
NEPHROTOXICITY
There is no evidence of an increased risk of nephrotoxicity in the elderly (136) . Cisplatin at a dose of 60-100 mg/m 2 can be safely administered to elderly patients (137, 138) .
MUCOSITIS
For all antineoplastic agents interfering with cell division, the oral mucosa is one of the target tissues most commonly affected. Mucositis is typically observed after the use of methotrexate, 5-fluorouracil, doxorubicin and bleomycin (139, 140) . The severity of mucositis may be affected by aging, because age-related depletion of mucosal stem cells leads to delayed renewal of epithelial cells in the mucosa (141) (142) (143) . In clinical trials, however, an increased degree of mucositis is not demonstrated in the elderly.
EFFICACY OF CHEMOTHERAPY

TUMOR CELL SENSITIVITY TO CHEMOTHERAPY
Little information is available on the chemosensitivity of tumors from ordinary experimental studies on a correlation between the age of animals and tumor growth, or from histopathological studies on the association between the age of patients and both tumor type and differentiation (144, 145) . Recent advances in cell biology, however, are yielding new findings from which we can understand the PD of tumor cells and aging. Proposed age-related changes in tumor cells are overexpression of p-glycoprotein, a higher concentration of glutathione reductase, increased hypoxia, abnormal protein synthesis with production of abnormal topoisomerase I and II, alteration in intracellular metabolism of drugs, and decreased DNA repair of genotoxic lesions (23, 144, (146) (147) (148) (149) . Of these, an association between increased p-glycoprotein expression and a poor complete remission rate has been demonstrated in elderly patients with acute leukemia (150-152).
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RESULTS OF CLINICAL TRIALS FOR SOLID TUMORS
According to a review of 19 ECOG trials involving 5459 patients (of these, 935 were aged ?:-70 years), in general, there is no meaningful difference in response to chemotherapy and survival between elderly and younger patients with solid tumors (96) . However, further discussion is necessary in some fields. Although chemotherapy for metastatic breast cancer in elderly patients produces a response rate and survival comparable to those in younger patients (67, 153) , adjuvant chemotherapy following surgery does not appear to be beneficial in patients aged ?:-70 years (154) . In the treatment of small-cell lung cancer, advanced age is an adverse prognostic factor in some studies (155) (156) (157) , but not in others (68, 69, 158, 159) . Begg et al. (96) reported in 1983 that advanced age was associated with poor tumor response and survival in patients with ovarian cancer. Recent experience, however, revealed that progression-free survival and overall survival of these patients were not affected by age (160) .
RESULTS OF CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
The influence of aging on treatment outcome largely depends on the type of malignancy. There is no difference in the response rate to chemotherapy and survival between elderly and. younger patients with myeloma (71), whereas elderly patients with Hodgkin's disease (72,16 I) have poorer responses and survival than younger patients. Results of treatment for non-Hodgkin lymphoma are controversial (73) (74) (75) (162) (163) (164) (165) . Advancing age is associated with suppressed rates of response to chemotherapy and survival in patients with leukemia (76, 77, 162, 166, 167) , although there are clinical trials providing exceptions (168, 169) .
LIMITATION OF THIS REVIEW AND FUTURE DIRECTIONS
Because most clinical studies reviewed here are retrospective, we should evaluate these results with caution. Toxicity data would be reliable if each patient were queried specifically as to the occurrence of various possible adverse effects. However, because it is often difficult to predict an uncommon adverse reaction to a drug, toxicity relatively common in elderly patients but rare in younger patients, e.g. central neurotoxicity such as dementia, may be overlooked. Comparison of survival between elderly and younger patients may lead to a biased conclusion, because other prognostic factors are not controlled.
Since elderly patients entered in clinical trials are highly selective, results obtained in these trials cannot fit all elderly patients who need cytotoxic therapy. Oshita et al. (170) prospectively evaluated the feasibility of cisplatin-based chemotherapy in patients aged ?-75 years with advanced lung cancer who had normal organic functions and ECOG performance status scores of 0-1. Of 34 patients with lung cancer, only 10 (29%) were eligible for this study. The reasons for exclusion were ischemic heart disease in 14, poor performance status in 11, renal dysfunction in 10 and abnormal ECG without ischemia in nine patients, and eight patients had two or more reasons.
The following issues should be studied prospectively in future trials. First, the standard chemotherapy established for non-elderly patients may be effective as well in the elderly with acceptable toxicity. Second, dose modification based on PK would be useful in the treatment of these patients. Gelman and Taylor (171) successfully reduced the toxicity of chemotherapy consisting of cyclophosphamide, methotrexate and 5-fluorouracil in women over age 65 with advanced breast cancer, without a decrease in efficacy, by modifying the initial doses of cyclophoshamide and methotrexate in proportion to pre-treatment creatinine clearance. Third, hematopoietic growth factors may be of great value in the elderly, although they produce only limited benefits in younger patients (172, 173) . Several randomized studies demonstrated that both mortality associated with neutropenia and survival were significantly improved by using these cytokines in elderly patients with acute leukemia (174, 175) . Finally, a patient's tolerance to chemotherapy would correlate better with 'biological age' than with'chronological age' , because the rate of aging is not uniform among all individuals. This measure could be estimated from external appearance, physical strength, physiological function tests and laboratory examinations (176, 177) . Among important fields of future research is identifying biomarkers which are validated and weighed according to their correlation with the degree of chemotherapy-induced toxicity, mortality and survival.
As the size of the geriatric population grows, it is increasingly important to be familiar with cancer treatment in this group. Advanced chronological age alone is not always a poor prognostic factor, and many elderly patients with cancer will benefit from chemotherapy. To answer many questions regarding the optimal treatment for these patients, the influence of age should be analyzed by a multivariate approach in future studies.
